JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $30

Benzinga · 15h ago
JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price target from $34 to $30.